CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis

• Market Cap: $207.52M
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: N/A
• EPS Growth: 5.51%
• Country: US
• Employees: 55
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 51,881,134
• 10 Day Avg. Volume: 141,089
• 30 Day Avg. Volume: 1,592,597
• PEG Ratio: 0.06
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 156.16
• P/FCF Ratio: -2.21
• Enterprise Value/Market Cap: 0.06
• Enterprise Value/Revenue: 3.44
• Enterprise Value/Gross Profit: 3.86
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: $9.00
• Price Target Upside: 132.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $4.00 ▲(3.36% Upside)

The score is held down primarily by large ongoing losses and significant cash burn, reinforced by weak technical momentum (below key moving averages with negative MACD). Offsetting these risks, the GSK collaboration and related funding potential is a meaningful positive catalyst, while valuation remains constrained by unprofitable earnings and no dividend support.

Positive Factors

Strategic collaboration with GSK

The GSK partnership structurally validates CAMP4’s RNA platform, provides meaningful non-dilutive near-term cash ($17.5M) and large milestone/royalty upside, and transfers late‑stage development, regulatory and commercialization risk to GSK, improving the firm’s long-term capital efficiency and commercial pathway.

High gross margins and improving revenue

Strong gross margins (~89%) indicate scalable, low-cost discovery and early‑stage development economics. Combined with recent ~26% revenue growth, this suggests the business model can generate high incremental margins as programs or collaborations scale, supporting durable operating leverage if topline growth persists.

Modest leverage and balance-sheet flexibility

Relatively low reported debt provides financial flexibility to support continued R&D and strategic partnerships without immediate bank leverage pressure. This modest leverage profile increases options for funding (collaborations, equity) and reduces bankruptcy risk, aiding multi‑period program execution if cash runway is managed.

Negative Factors

Persistent cash burn and negative free cash flow

Consistent multi‑period negative operating and free cash flow indicates the company must continually secure external funding or partnerships to sustain operations. This structural cash burn limits autonomy, increases financing dependence, and poses dilution or covenant risk if revenue scale or major collaborations do not materialize.

Large ongoing operating losses

Operating expenses far exceed current revenue, creating a long horizon to profitability unless revenues scale materially or costs are reduced. Persistently negative EBIT and returns on equity undermine internal cash generation and increase the probability of repeated external financing rounds or strategic tradeoffs on program prioritization.

Reliance on equity financing

Frequent use of equity raises to fund operations signals structural dependence on capital markets and creates dilution risk for shareholders. This reliance can constrain long‑term allocation decisions, and if market conditions tighten, CAMP4 may face higher funding costs or forced program cuts absent stronger operational cash generation.

CAMP4 Therapeutics Corporation Business Overview & Revenue Model

Company Description

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

How the Company Makes Money

CAMP4 Therapeutics primarily generates revenue through several key streams, including research collaborations, licensing agreements, and potential milestone payments from partnerships with larger pharmaceutical companies. The company often enters into strategic partnerships to co-develop its therapeutic candidates, which can provide upfront payments and ongoing funding for research and development. Additionally, CAMP may receive royalties on sales of products developed from its proprietary technologies. The success of its revenue model is significantly bolstered by the strong demand for innovative treatments in the biotechnology sector and the increasing interest from investors and partners in RNA-based therapies.

CAMP4 Therapeutics Corporation Financial Statement Overview

Summary

Revenue is improving and gross margin is very strong (~89%), but the business is still dominated by very large operating losses (TTM EBIT about -$53.3M) and heavy cash burn (TTM FCF about -$47.7M). Leverage is currently modest, yet persistent losses create ongoing financing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue improved to ~$3.8M (+26.4% growth) and gross margin remained strong (~89%), but the company continues to post very large operating losses (TTM EBIT about -$53.3M) and a deeply negative net margin. Losses have stayed elevated across periods, indicating the cost base is far ahead of the current revenue level; while topline is improving versus the 2024 annual level, profitability remains a key weakness.

Balance Sheet

Leverage looks modest in TTM (Trailing-Twelve-Months), with debt of ~$6.3M against ~$58.7M of equity (low debt vs equity), suggesting good balance-sheet flexibility at present. However, returns on equity are meaningfully negative (reflecting ongoing losses), and the historical trend includes periods of negative equity and very high leverage (notably in 2023), which highlights prior balance-sheet stress and the importance of maintaining capital levels if losses persist.

Cash Flow

Cash generation remains weak: TTM (Trailing-Twelve-Months) operating cash flow is about -$47.1M and free cash flow about -$47.7M, implying a sizable ongoing cash burn. A positive note is that free cash flow roughly tracks net income in TTM (indicating losses are not being materially worsened by non-cash distortions), but the overall funding need remains high given consistently negative operating and free cash flow across recent periods.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.80M	652.00K	350.00K	0.00	295.84M	308.59M
Gross Profit	3.39M	652.00K	350.00K	0.00	121.89M	122.41M
EBITDA	-53.58M	-51.39M	-50.20M	-44.12M	7.49M	18.13M
Net Income	-53.40M	-51.79M	-49.29M	-44.19M	-31.15M	-21.16M
Balance Sheet
Total Assets	86.39M	78.31M	54.95M	102.55M	402.29M	441.82M
Cash, Cash Equivalents and Short-Term Investments	75.25M	64.04M	38.38M	83.19M	91.11M	91.69M
Total Debt	6.35M	8.65M	11.69M	12.39M	209.17M	210.80M
Total Liabilities	27.73M	15.16M	178.68M	180.08M	322.11M	342.50M
Stockholders Equity	58.67M	63.14M	-123.73M	-77.53M	80.18M	99.32M
Cash Flow
Free Cash Flow	-47.68M	-46.00M	-44.83M	-42.57M	-17.52M	17.23M
Operating Cash Flow	-47.13M	-45.56M	-44.16M	-38.54M	-4.22M	28.59M
Investing Cash Flow	-785.00K	-441.00K	-678.00K	-4.03M	-7.58M	-13.69M
Financing Cash Flow	120.37M	71.66M	301.00K	100.16M	-2.64M	-27.32M

CAMP4 Therapeutics Corporation Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Negative. The current price of 3.87 is below the 20-day moving average (MA) of 5.33, below the 50-day MA of 4.98, and above the 200-day MA of 2.93, indicating a neutral trend. The MACD of -0.41 indicates Positive momentum. The RSI at 35.80 is Neutral, neither overbought nor oversold. The STOCH value of 15.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAMP.

CAMP4 Therapeutics Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARTV	58 Neutral	$109.72M	-1.28	-47.96%	―	-100.00%	-17.10%
RLMD	57 Neutral	$289.67M	-2.18	-196.79%	―	―	37.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAMP	49 Neutral	$207.52M	-1.58	-172.70%	―	―	5.51%
INKT	48 Neutral	$58.86M	-4.04	―	―	―	21.48%
OSTX	45 Neutral	$50.00M	-1.69	-914.04%	―	―	-133.00%
BYSI	43 Neutral	$63.74M	―	―	―	―	―

CAMP4 Therapeutics Corporation Corporate Events

CAMP4 Therapeutics updates corporate investor presentation materials

On January 9, 2026, CAMP4 Therapeutics Corporation updated its corporate presentation for the investment community, making the revised materials available through the investors section of its website and furnishing them as an exhibit to a regulatory filing. The move reflects the company’s ongoing practice of using slide decks and presentations to provide investors with current information on its business, while clarifying that these materials are being furnished rather than formally filed under U.S. securities laws, which limits their exposure to certain regulatory liabilities and incorporation into other securities filings.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics Restructures Leases and Expands Facilities

On December 22, 2025, CAMP4 Therapeutics Corporation amended its existing lease for approximately 30,760 square feet of laboratory and office space at One Kendall Square in Cambridge, Massachusetts, accelerating the termination of that lease to 30 days after the commencement of a new lease in Watertown, while securing an abatement of base rent at the Cambridge site from October 1, 2025 until the early termination date, contingent on remaining in compliance with both leases. On the same date, the company signed a new lease for about 44,000 square feet of laboratory and office space at 100 Talcott Avenue in Watertown, Massachusetts, running through June 30, 2030, with base rent starting at $40 per square foot and increasing annually, and agreed to pay a $2.1 million lease modification fee in exchange for additional rent abatement at the new site, a move that expands its footprint and restructures its real estate costs in a key biotech hub.

The most recent analyst rating on (CAMP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics Announces $28 Million Common Stock Offering

On December 18, 2025, CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC to offer 5,000,000 shares of its common stock at $6.00 per share, all sold by the company, with expected net proceeds of approximately $28 million and an anticipated closing on or about December 19, 2025, subject to customary conditions. The deal includes standard underwriting terms such as indemnification provisions and a 60-day lock-up restricting share sales by the company, executives, directors and certain stockholders, while allowing sales under its at-the-market program after 30 days, underscoring CAMP4’s continued reliance on equity financing to support its business and potentially affecting share liquidity and ownership dynamics in the near term.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4, GSK form RNA therapeutics collaboration agreement

On December 17, 2025, CAMP4 Therapeutics entered into a strategic research, collaboration and license agreement with GSK to discover and develop antisense oligonucleotide therapeutics targeting regulatory RNAs linked to multiple neurodegenerative and kidney disease gene targets, combining CAMP4’s regRNA mapping and RAP Platform-based ASO discovery capabilities with GSK’s global development and commercialization infrastructure. Under the deal, CAMP4 granted GSK an exclusive worldwide license to develop and commercialize resulting compounds and products, will conduct early research to deliver lead ASO series before GSK assumes full responsibility for clinical development, regulatory work, manufacturing and commercialization, and will receive a $17.5 million upfront payment plus eligibility for up to $440 million in development and commercial milestones and tiered royalties, positioning CAMP4 to monetize its RNA platform while potentially expanding its presence in neurodegenerative and renal disease markets without bearing late-stage development risk.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.